BACKGROUND: Obesity increases the risk of heart failure (HF), but a significant survival benefit in obese patients has been described once they have been diagnosed with HF. There is little information about the effects of weight loss among patients with HF. We aimed to assess the frequency of weight loss in patients with HF from the RICA Registry and whether weight loss is associated with mortality. METHODS: We investigated weight changes in 731 patients with HF and analysed the effect of weight loss of 5% or more of their baseline bodyweight during follow-up. RESULTS: 419 (57.3%) patients lost weight during follow-up but only 152 (20.8%) lost at least 5% of the baseline bodyweight. We did not find significant differences in demographic, clinical, functional and analytical parameters between patients with and without weight loss or 5% or more of their bodyweight. We observed a significant improvement in the mean NYHA functional class value and a non-significant improvement in the LVEF in all patients. A significant decrease in the natriuretic peptide levels was only observed in the patients who lost weight. Survival rates at 1year follow-up for patients with and without weight loss or 5% or more were 75.7% (95% CI: 67.1-84.3%) and 77.1% (95% CI: 72.8-81.4%), respectively (p=0.92). Re-admission rates for patients with and without weight loss were 52.7% (95% CI: 42.9-62.43%) and 50.0% (95% CI: 45.3-54.7%), respectively (p=0.34). CONCLUSIONS: Significant weight loss occurred in 20.8% of patients with HF. Weight loss was not associated with mortality or readmission.
BACKGROUND: Obesity increases the risk of heart failure (HF), but a significant survival benefit in obesepatients has been described once they have been diagnosed with HF. There is little information about the effects of weight loss among patients with HF. We aimed to assess the frequency of weight loss in patients with HF from the RICA Registry and whether weight loss is associated with mortality. METHODS: We investigated weight changes in 731 patients with HF and analysed the effect of weight loss of 5% or more of their baseline bodyweight during follow-up. RESULTS: 419 (57.3%) patients lost weight during follow-up but only 152 (20.8%) lost at least 5% of the baseline bodyweight. We did not find significant differences in demographic, clinical, functional and analytical parameters between patients with and without weight loss or 5% or more of their bodyweight. We observed a significant improvement in the mean NYHA functional class value and a non-significant improvement in the LVEF in all patients. A significant decrease in the natriuretic peptide levels was only observed in the patients who lost weight. Survival rates at 1year follow-up for patients with and without weight loss or 5% or more were 75.7% (95% CI: 67.1-84.3%) and 77.1% (95% CI: 72.8-81.4%), respectively (p=0.92). Re-admission rates for patients with and without weight loss were 52.7% (95% CI: 42.9-62.43%) and 50.0% (95% CI: 45.3-54.7%), respectively (p=0.34). CONCLUSIONS: Significant weight loss occurred in 20.8% of patients with HF. Weight loss was not associated with mortality or readmission.
Authors: Elisabet Zamora; Carles Díez-López; Josep Lupón; Marta de Antonio; Mar Domingo; Javier Santesmases; María Isabel Troya; Crisanto Díez-Quevedo; Salvador Altimir; Antoni Bayes-Genis Journal: J Am Heart Assoc Date: 2016-03-24 Impact factor: 5.501